Form 4 for SCLX Scilex Holding Co

Accepted 2025-01-06 00:00:00 ET · period of report 2025-01-02 · accession 0000950170-25-002437 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2025-01-06	2025-01-02	SCLX	SCLX Stock Acquisition JV LLC	10%	J - Other	—	-5.00M	55.07M	-8%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-01-02	J	D	5,000,000	—	55,068,585	D	—	—	(F1) Transferred pursuant to the terms of a Deferral and Consent Letter (collectively, the "Consent Letters") the Issuer and the Reporting Person entered into with each of (i) Nomis Bay Ltd and BPY Limited, (ii) Oramed Pharmaceuticals Inc. ("Oramed") and (iii) 3i, LP, respectively (collectively, the "Noteholders") for the deferral of certain amortization payments owned by the Issuer to the Noteholders. Under the terms of the Consent Letters and in consideration for such deferrals and to limit the Noteholders' right to exercise certain secured creditor remedies (including recourse against the assets of the Reporting Person as a grantor under the Security Agreement (as defined in the Consent Letters)), (F2) (continued from footnote 1) the Reporting Person transferred to the Noteholders an aggregate of 5,000,000 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person, of which 2,500,000 shares were delivered to Oramed, 720,000 shares were delivered to BPY Limited, 1,280,000 shares were delivered to Nomis Bay Ltd, and 500,000 shares were delivered to 3i, LP.